As cases COVID-19 surge around the country, driven by the omicron variant, there’s some good news too. Two new treatments have been approved by the Food and Drug Administration — both of them pills shown to reduce serious illness, hospitalization and death among high-risk patients.
So what’s the difference between Merck’s Molnupiravir and Pfizer’s Paxlovid? And what other treatments are available as we head into the third year of the pandemic?
Here & Now‘s Celeste Headlee checks in with virologist Angela Rasmussen at the University of Saskatchewan.
This article was originally published on WBUR.org.
Copyright 2021 NPR. To see more, visit https://www.npr.org.
